In support of these findings, Ishibashi et al. [14] reported that three years of SGLT-2 inhibitor therapy in patients with modestly controlled type 2 diabetes significantly improved neuropathy outcomes and decelerated nephropathy progression. Here, SLC5A2 is linked to type 2 diabetes mellitus.